Get started
Author

Jingyu Xu

Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM)
2024 · Huishou Fan, Bing Wang, et al. · Clinical Cancer Research · 22
PDF
Development and validation of an individualized and weighted Myeloma Prognostic Score System ( MPSS ) in patients with newly diagnosed multiple myeloma
2024 · Xuehan Mao, Wenqiang Yan, et al. · American Journal of Hematology · 20
PDF
[Recommendations of diagnosis and treatment of primary Sjögren's syndrome in China].
2020 · W Zhang, X M Li, et al. · PubMed · 17
LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma
2024 · Lixin Gong, Hao Sun, et al. · Haematologica · 16
Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma
2023 · Wenqiang Yan, Jingyu Xu, et al. · Cancer · 15
PDF
Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing
2024 · Jian Cui, Xiaoyun Li, et al. · Clinical Cancer Research · 14
PDF
Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
2023 · Jiahui Liu, Wenqiang Yan, et al. · Cancer Research Communications · 10
PDF
Clinical implications of residual normal plasma cells within bone marrow across various disease stages in multiple myeloma
2024 · Wenqiang Yan, Lihui Shi, et al. · Leukemia · 9
Fluorescence in situ hybridization reveals the evolutionary biology of minor clone of gain/amp(1q) in multiple myeloma
2024 · Jian Cui, Yuntong Liu, et al. · Leukemia · 9
PDF
Longitudinal genetically detectable minimal residual disease by fluorescence in situ hybridization confers a poor prognosis in myeloma
2024 · Jian Cui, Tengteng Yu, et al. · Therapeutic Advances in Medical Oncology · 3
A Phase 2 Study of CART-ASCT-CART2 Sandwich Regimen Treatment in Patients with Primary Plasma Cell Leukemia
2024 · Jingyu Xu, Shuaishuai Zhang, et al. · Blood · 2
PDF
Analysis of Diagnosis and Treatment Pattern for Newly Diagnosed Multiple Myeloma in China over 20 Years
2024 · Jingyu Xu, Yuntong Liu, et al. · Blood · 2
MAF translocation remains a strong prognostic factor despite concurrent chromosomal abnormalities
2024 · Yuntong Liu, Rui Lv, et al. · Haematologica · 2
PDF
Immunotherapy for multiple myeloma: new chances and hope
2023 · Jingyu Xu, Gang An, et al. · Cancer Biology and Medicine · 2
PDF
CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities
2024 · Yuntong Liu, Weiwei Sui, et al. · Blood · 1
PDF
[Clinical characteristics and prognosis of 46 patients with macrofocal multiple myeloma].
2022 · W W Yan, H S Fan, et al. · PubMed · 1
P1162: Zanubrutinib in Older Patients (pts) With Relapsed/refractory (r/r) Marginal Zone Lymphoma (mzl): Subgroup Analysis of the Magnolia Study
2022 · S. Opat, B. Hu, et al. · HemaSphere · 1
[Evaluation of asthma disease perception from China national asthma control survey].
2018 · W Q Wang, J T Lin, et al. · PubMed · 1
Exploring temporal trends and influencing factors for upper digestive tract cancers in Guangzhou, China: 2010–2020
2025 · Yawen Wang, Boheng Liang, et al. · Cancer Epidemiology
The specific transcriptional profile and clonal selection of monoclonal gammopathy of undetermined significance-like behavior predict an exceptionally favorable prognosis in multiple myeloma
2025 · Wenqiang Yan, Chen Qiu, et al. · Haematologica
PDF
The Monoclonal Gammopathy of Undetermined Significance-Like (MGUS-like) Classifier Stratifies Prognosis in Multiple Myeloma: Results from Real-World Data in Chinese Population
2025 · Wenqiang Yan, Jieqiong Zhou, et al. · Clinical Lymphoma Myeloma & Leukemia
Data from Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing
2024 · Jian Cui, Xiaoyun Li, et al.
Data from Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing
2024 · Jian Cui, Xiaoyun Li, et al.
Supplementary Data 2 from Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing
2024 · Jian Cui, Xiaoyun Li, et al.
Supplementary Data 1 from Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing
2024 · Jian Cui, Xiaoyun Li, et al.
Works count: 114
Citation count: 147
H-index: 9
I10-index: 7
Year
Topic
Type